ABSTRACT
In C. elegans, the TGFβ-like type II receptor daf-4 is required for two distinct signaling pathways. In association with the type I receptor daf-1, it functions in the dauer pathway. In addition, it is also required for body size determination and male tail patterning, roles which do not require daf-1. In an effort to determine how two different signals are transmitted through daf-4, we looked for other potential signaling partners for DAF-4. We have cloned and characterized a novel type I receptor and show that it is encoded by sma-6. Mutations in sma-6 generate the reduced body size (Sma) and abnormal mail tail (Mab) phenotypes identical to those observed in daf-4 and sma-2, sma-3, sma-4 mutants (C. elegans Smads), indicating that they function in a common signaling pathway. However, mutations in sma-6, sma-2, sma-3, or sma-4 do not produce constitutive dauers, which demonstrates that the unique biological functions of daf-4 are mediated by distinct type I receptors functioning in parallel pathways. We propose that the C. elegans model for TGFβ-like signaling, in which distinct type I receptors determine specificity, may be a general mechanism of achieving specificity in other organisms. These findings distinguish between the manner in which signaling specificity is achieved in TGFβ-like pathways and receptor tyrosine-kinase (RTK) pathways.
INTRODUCTION
One of the primary signaling pathways is the TGFβ superfamily of extracellular ligands, which provides a diverse array of developmental and proliferation control cues. The dpp/BMP subfamily regulates many important developmental events, including dorsal-ventral patterning, mesoderm induction, and osteogenesis (Irish and Gelbart, 1987; Panganiban et al., 1990; Wozney et al., 1988; reviewed in Padgett et al., 1998). In Drosophila, dpp, 60A, and screw encode TGFβ-like ligands and are required during the embryonic and/or the pupal stages to regulate development (Padgett et al., 1987; Arora et al., 1994; Chen et al., 1998; Khalsa et al., 1998). In C. elegans, the daf-7 gene, which encodes a divergent ligand, is involved in dauer formation (Ren et al., 1996), and unc-129 is involved in axonal pathfinding (Colavita et al., 1998). In Drosophila and C. elegans, there are other TGFβ-like ligands that have been identified by their respective genome sequencing projects, but their functions have not been reported.
Members of the TGFβ superfamily share a conserved C-terminal region that is cleaved from a precursor polypeptide. Subsequently, homo-or heterodimerization of these domains yields functional bioactive molecules. Metalloproteases whose activity is required for the biological function of the ligands have been identified in several organisms (Childs et al., 1994; Finelli et al., 1994; Padgett et al., 1997). Signaling is mediated by two receptor serine-threonine kinases that heterodimerize after ligand binding to transduce the signal to downstream components. Two classes of receptor kinases have been identified, the type I and II families, that are both essential to this role. The two classes of receptors are homologous, but there is greater similarity among the members within each group. A distinguishing feature of type I receptors is the existence of a glycine-serine rich stretch of residues, the GS domain, preceding the kinase region.
A model of receptor activation and signal transduction has been developed for TGFβ receptors in vertebrates (Miyazono et al., 1994; Ventura et al., 1994; Wrana et al., 1994; Liu et al., 1995; Weis-Garcia and Massagué 1996). According to this model, the type II receptor kinases are constitutively phosphorylated and form a complex with a corresponding type I receptor upon ligand binding. Phosphorylation of the GS domain by the type II receptor then renders the type I kinase active. In this manner, the active receptor complex is able to transduce the signal from the ligand to downstream intracellular effectors. Further work has demonstrated that the signaling complex consists of a hetero-oligomeric or tetrameric combination of type I and type II receptors, and that type II receptors may exist freely as dimers preceding interaction with ligand (Yamashita et al., 1994).
There are two well-characterized TGFβ-like pathways in C.elegans, the Sma/Mab (small and male abnormal) and dauer pathways, and a recently discovered third pathway involving unc-129 (Colavita, et al., 1998). Previously, the daf-1 and daf-4 genes were shown to encode TGFβ-like serine-threonine kinase receptors of the type I and II families respectively, and it was demonstrated that DAF-4 is capable of binding vertebrate BMP-4 (Riddle et al., 1981; Georgi et al., 1990; Estevez et al., 1993). Mutations of daf-4 result in small body size, male tail deformities, constitutive dauer formation, and egg-laying abnormalities. Although normal with respect to body size and male tail morphology, daf-1 mutants share the dauer and egg-laying defects of daf-4. The model for receptor activation and signaling suggests that daf-1 and daf-4 may function together to transduce a dauer signal; however, this does not explain the additional phenotypes observed in daf-4 animals. Investigations into other molecules that are necessary to transduce the daf-4 signal regulating body size and male tail development led to the cloning and characterization of the C. elegans sma-2, sma-3, and sma-4 genes, which were shown to encode Smads that function downstream of daf-4 (Savage et al., 1996). These genes, when mutant, produce the reduced body size (Sma), and male tail abnormal (Mab) defects evident in the daf-4 phenotypes, and were found to function non-redundantly in a common pathway (Savage et al., 1996). Collectively, Mad, sma-2, sma-3, and sma-4, and their homologs constitute the Smad family of transducers (Derynck et al., 1996).
The discovery and characterization of the Smad protein family has shown that they are integral signal transducing elements in diverse TGFβ-like pathways (Sekelsky et al., 1995; Baker et al., 1996; Hoodless et al., 1996; Liu et al., 1996; Savage et al., 1996). The Smad members identified thus far in several organisms, including C. elegans, Drosophila, and vertebrates fall into three related classes: receptor-regulated (R-Smads), common (Co-Smads), and antagonistic (Anti-Smads) (reviewed by Attisano and Wrana, 1998; Heldin et al., 1997; Massagué, 1998; Padgett et al., 1998). Phosphorylation of receptor-regulated Smads by a respective type I kinase has been demonstrated to be critical for their ability to mediate a TGFβ-like signal (Macias-Silva et al., 1996; Zhang et al., 1996; Kretzchmar et al., 1997). A nuclear role for these transducers has been established by the demonstration that the phosphorylated Smads translocate to the nucleus as a heteromeric complex consisting of receptor-regulated and common Smads, and interact with transcription factors and promoter regions of target genes to regulate expression (Chen et al., 1996; Lagna et al., 1996; Kim et al., 1997; Wu et al., 1997; Feng et al., 1998; Janknecht et al., 1998). In vertebrates, FAST-1, a winged-helix forkhead homolog, has been observed to associate with Smad4 in signaling-responsive transcriptional regulatory complexes (Chen et al., 1996, 1997). In humans, mutations in the Smads have been implicated in tumor progression, presumably through a lack of response to growth-influencing cellular communication signals (Eppert et al., 1996; Hahn et al., 1996). The identification of the antagonistic Smads, human Smad6 (Immamura et al., 1997; Hata et al., 1998), human Smad7 (Hayashi et al., 1997; Nakao et al., 1997), and Drosophila DAD (Tsuneizumi et al., 1997) as competitive negative regulators of TGFβ-like signaling pathways has yielded an additional mechanism by which the activity of the pathway is intracellularly regulated.
In this work, we report the identification and characterization in C. elegans of a novel type I receptor encoded by sma-6, and show that it is an essential signaling component of the Sma/Mab developmental pathway. Based on our results, the implications for TGFβ signaling in general are that first, two dissimilar type I receptors may share a common type II receptor signaling partner; and second, that the corresponding developmental roles of the type I receptors can be unique through the utilization of distinct downstream transducers. Furthermore, this feature of C. elegans TGFβ signaling contrasts with the receptor tyrosine kinase system in Drosophila, in which three pathways utilize the same MAPK, but achieve specificity by activating different transcription factors (Brunner et al., 1994).
MATERIALS AND METHODS
C. elegans strains and culture
Strains were manipulated and cultured using standard methods (Brenner, 1974). The strain N2 (Bristol) was used as the wild-type reference. Unless stated otherwise, all strains were maintained at 20°C.
Isolation and characterization of sma-6 cDNAs
The degenerate primer pair 5′GCCGGAATTCCAYCGNGAYATH-AARTCNAARAA3′ and 5′GCCGTCTAGATCNAGNAYYTCNG-GNGCCATRTA3′ was used to amplify a 150 bp PCR fragment corresponding to the conserved kinase regions III and VI of TGFβ/BMP receptors from oligo-dT primed reverse-transcribed total RNA extracted from N2 animals. The RT-PCR was performed according to the manufacturer’s protocol (Perkin-Elmer), using 2 μg of total RNA. The conditions for the PCR reaction were: 35 cycles of 1 minute at 94°C, 1 minute at 55°C, and 1 minute 30 seconds at 72°C. The bands of interest were purified, cloned into pBS SK+ at the EcoRI and XbaI sites, and sequenced. Inserts corresponding to sma-6 were then excised and radiolabeled to probe a cDNA library. An N2 cDNA library in λZap (courtesy of R. Barstead) was screened with the 150 bp PCR fragment. Seven independent cDNA clones in pBS SK+ (Stratagene) were sequenced at the 5′ and 3′ termini. An approx. 2.25 kb cDNA containing the expected secretion signal and conserved intracellular kinase region was judged to be full-length, and was subsequently sequenced. Comparison with cosmid C32D5 sequence (C. elegans Genome Sequencing Consortium) verified the sequence.
Isolation of sma-6 genomic fragments
The 2.25 kb fragment corresponding to the sma-6 cDNA was radiolabeled and used to probe a C. elegans genomic library in EMBL3A (courtesy of Dr Philip Anderson). Phage inserts were purified and mapped through restriction analyses using the known cosmid sequence. Inserts covering the sma-6 gene were used for generating a rescuing construct.
Transformation constructs
A genomic clone encompassing the sma-6 region was digested with PstI/EagI to generate a approx. 9 kb fragment which was subcloned into the Bluescript (SK+) vector to generate pSK1. pRF4, bearing a dominant rol-6 mutation, was used as a transformation marker (Mello et al., 1991). Stable transgenic lines were generated through selection of transformed progeny bearing the Rol phenotype, and rescue of the body size defect was assessed. pRF4 injected alone was not sufficient for rescue of the sma-6 phenotype.
A 2 kb fragment including upstream regulatory sequences and the first four residues of SMA-6 was used to generate a translational fusion with the lacZ gene in the vector pPD95.03 (courtesy of A. Fire).
Transformed lines bearing a stable extrachromosomal array were selected and subjected to γ-ray irradiation followed by selection for stably integrated lines. Animals were then stained to examine the expression of lacZ (Fire et al., 1990; Fire, 1992).
Generation of sma-6 alleles
sma-6(wk10) was identified in a non-complementation screen for sma-6 mutants. unc-4 (e120)II homozygous hermaphrodites were mutagenized with the standard EMS protocol (Brenner, 1974). Homozygous sma-6(e1482)II males were mated with mutagenized parental Unc animals, and the subsequent F1 progeny were scored for a Sma Non-Unc phenotype, representing the cross progeny homozygous for a mutation in sma-6. sma-6(wk7), sma-6(wk8), and sma-6(wk9) were recovered in an F2 screen for Sma animals (C. Savage and R. W. P., unpublished data) and failed to complement sma-6. sma-6(wk11) was isolated in a screen for transposition induced Sma mutants (C. Savage and R. W. P., unpublished).
Characterization of mutant alleles
All sma-6 mutants were outcrossed at least twice. sma-6 him-5(e1490)V animals were generated to facilitate male tail analyses. Animals were propagated on plates and harvested with M9 buffer and transferred to tubes, followed by rounds of washing. NaN3 was added to a concentration of 50 mM to anesthetize the animals. Approximately 100 animals were then pipetted onto 5% agar pads in batches and examined with Nomarski optics to score spicules or rays. Only complete fusions of rays were scored as defective (partial fusions include fusions of only the distal portion of the rays). sma-6/Df animals were generated by crossing N2 males into sma-6 hermaphrodites and using the heterozygous F1 males to cross into strains SP788 unc-4(e120) mnDf96/mnC1 dpy-10(e128) unc-52(e444)II and SP543 mnDf30 unc-4(e120)/mnC1 dpy-10(e128) unc-52(e444)II to obtain F2sma-6/Df males. LT234 sma-6(e1482) unc-4(e120)II; sma-4(e805)III; him-5(e1490)V was generated by crossing sma-4(e805); him-5(e1490) males into sma-6(e1482) unc-4(e120) animals. Wild-type F1 hermaphrodites were then transferred to individual plates, and allowed to self-fertilize. Sma Non-Unc F2 animals were isolated and transferred to individual plates. Sma Unc animals were isolated and transferred in the F3 generation, and the F4 generation was examined for the Him phenotype. Complementation tests were performed to confirm the homozygosity for sma-6(e1482) and sma-4(e805).
Genetic interaction between dauer and Sma/Mab pathways
Mutant strains consisting of sma-[2,3,4,6] daf-1; him-5 were constructed by first crossing him-5(e1490) males into daf-1 hermaphrodites. Doubly heterozygous [daf-1(m40) or daf-1(m213)]IV; him-5(e1490)V males were then crossed into sma-[2,3,4,6] hermaphrodites. Non-Sma hermaphrodites, representing the cross progeny, were picked onto separate plates. The Sma progeny were then selected from these plates and allowed to self-fertilize, and the progeny were examined over two generations for the Sma Daf Him phenotypes, representing the homozygous state. These animals were transferred to individual plates, and allowed to self-fertilize for an additional generation for confirmation.
Sequencing and analyzing molecular lesions in sma-6
Primers corresponding to the termini of the sma-6 gene were used to amplify a 2.5 kb product from the mutant strains CB1482, LT191, and LT78 using Pfu polymerase (Stratagene) to minimize the error rate. Independent clones were sequenced using an automated sequencer (Applied Biosystems). Comparison with the C32D5 cosmid sequence (C. elegans Sequencing Consortium) was used to identify polymorphisms. Sequence analyses were performed using the Wisconsin package (GCG Group). Genefinder (courtesy of Phil Green and Ladeana Hiller, Washington University) was used to predict open reading frames on an Irix platform. AceDB was used for C. elegans-specific genetic analyses.
RESULTS
Molecular cloning of a novel type I TGFβ-like receptor
The hypothesis that an unknown type I receptor participated with daf-4 to signal through the sma-2, sma-3 and sma-4 genes argued for the existence of an additional type I receptor which, when mutant, confers the small body size and male tail abnormal phenotypes. However, no preexisting mutants had been identified that exhibited both of these specific characteristics. The conserved intracellular kinase regions of the TGFβ superfamily receptors provided a strong region of homology suitable to employ an RT-PCR approach. Since this pathway was a BMP-like pathway, we chose to employ degenerate oligonucleotides corresponding to the conserved regions III and VI of Drosophila TKV and SAX type I kinase domains (Xie et al., 1994), RT-PCR was performed on total C. elegans total RNA. Several clones were sequenced and analyzed for homology with the type I receptor family. In addition to multiple instances of daf-4 and other non-transmembrane serine-threonine kinases, a BLAST search revealed that one of the clones resided on the C. elegans cosmid C32D5 in LGII. We obtained full-length cDNA clones using the PCR fragment as a probe and isolated multiple 2.2 kb clones, examination of which revealed they had the structure of a TGFβ-like receptor. The presence of an N-terminal signal sequence in the predicted protein indicated that the cDNA clone was full-length.
sma-6 encodes a BMP type I receptor
Cosmid C32D5 had been localized to the LGII in the central cluster by the C. elegans Genome Sequencing Project. In order to determine the biological role of the novel type I receptor, we sought candidate mutations for rescue. We examined the genetic region near C32D5 for genes which mutate to a Sma/Mab phenotype. Interestingly, the sma-6 locus, which exhibits a reduced body size when mutant, maps to the C32D5 region (Fig. 1A). sma-6 mutants, like mutants in sma-2, -3 and -4, appear uniformly reduced in body size, both with respect to width and length (Fig. 3B). To test if the new type I receptor corresponded to sma-6, we used a genomic clone of the receptor for transformation rescue of the canonical sma-6(e1482) allele. A 9 kb PstI/EagI subcloned genomic fragment containing the type I receptor and flanking regions of adjacent predicted genes was sufficient to rescue the sma-6(e1482) allele. By sequencing the region corresponding to the cDNA in sma-6(e1482) mutants, we identified a molecular lesion. These results indicate that sma-6 encodes the new receptor.
Molecular cloning of sma-6. (A) sma-6 genomic localization. The sma-6 transcript was localized to cosmid C32D5, which is on LGII. A 9 kb genomic fragment encompassing the predicted gene was used to rescue sma-6(e1482) animals. Strains SP788 and SP543 harboring heterozygous deletions mnDf30 and mnDf96, respectively, of the region containing sma-6 were utilized for deficiency analyses. (B)Genomic organization, domain structure and identified mutations in sma-6. The intron/exon organization of the sma-6 gene deduced from the cDNA is shown. The domain structure of SMA-6, including secretion, extracellular, transmembrane, GS domain, and kinase domains is similar to other type I kinases.
Molecular cloning of sma-6. (A) sma-6 genomic localization. The sma-6 transcript was localized to cosmid C32D5, which is on LGII. A 9 kb genomic fragment encompassing the predicted gene was used to rescue sma-6(e1482) animals. Strains SP788 and SP543 harboring heterozygous deletions mnDf30 and mnDf96, respectively, of the region containing sma-6 were utilized for deficiency analyses. (B)Genomic organization, domain structure and identified mutations in sma-6. The intron/exon organization of the sma-6 gene deduced from the cDNA is shown. The domain structure of SMA-6, including secretion, extracellular, transmembrane, GS domain, and kinase domains is similar to other type I kinases.
sma-6 encodes a type I receptor. (A) Receptor dendogram. Dendrograms were produced with the Pileup Program using the Wisconsin GCG Software Package, Genetic Computer Group, Madison, WI. SMA-6 is a member of the type I class of TGFβ-like receptors, and is more conserved than its counterpart in the C. elegans dauer pathway, DAF-1. Also shown are the Drosophila type I receptors SAX and TKV. (B)Amino-acid sequence alignment of C. elegans SMA-6, Drosophila THICK VEINS, and Xenopus laevis BMPR-I. Several cysteine residues that contribute to the extracellular framework of the type I receptor family are conserved in SMA-6. In addition, the conserved GS domain, a hallmark of the type I family and of phosphorylation, which is necessary for the activation of the type I kinase, is present in SMA-6 (boxed). This sequence has been deposited in GenBank (AF104017).
sma-6 encodes a type I receptor. (A) Receptor dendogram. Dendrograms were produced with the Pileup Program using the Wisconsin GCG Software Package, Genetic Computer Group, Madison, WI. SMA-6 is a member of the type I class of TGFβ-like receptors, and is more conserved than its counterpart in the C. elegans dauer pathway, DAF-1. Also shown are the Drosophila type I receptors SAX and TKV. (B)Amino-acid sequence alignment of C. elegans SMA-6, Drosophila THICK VEINS, and Xenopus laevis BMPR-I. Several cysteine residues that contribute to the extracellular framework of the type I receptor family are conserved in SMA-6. In addition, the conserved GS domain, a hallmark of the type I family and of phosphorylation, which is necessary for the activation of the type I kinase, is present in SMA-6 (boxed). This sequence has been deposited in GenBank (AF104017).
sma-6 is required for body size determination and male tail development. (A) Nomarksi micrographs of a wild-type male tail, (B) wild-type spicules, and (C) wild-type animal. The wild-type male tail is composed of laterally symmetric triplets of rays from 1 to 9, numbered anterior to posterior. (D) sma-6 male tail, (E) crumpled spicules of sma-6, and (F) sma-6 animal at same magnification as in C. The arrows in B and E point to spicules. The arrow in D points to a fusion of rays 6 and 7 in a sma null mutant.
sma-6 is required for body size determination and male tail development. (A) Nomarksi micrographs of a wild-type male tail, (B) wild-type spicules, and (C) wild-type animal. The wild-type male tail is composed of laterally symmetric triplets of rays from 1 to 9, numbered anterior to posterior. (D) sma-6 male tail, (E) crumpled spicules of sma-6, and (F) sma-6 animal at same magnification as in C. The arrows in B and E point to spicules. The arrow in D points to a fusion of rays 6 and 7 in a sma null mutant.
The sma-6 gene is composed of 12 exons spanning 2.7 kb of transcribed sequence and an additional 2 kb of possible upstream regulatory sequence, as deduced from the existence of a polyadenylation sequence in an adjacent predicted transcript using Genefinder. Analysis of the sma-6 primary structure indicated that it is homologous to other TGFβ-like type I receptors, and is more similar to the majority of other type I receptors than is daf-1 (Fig. 2A and 2B). The conserved N-terminal cysteine residues found in the extracellular domains of both type I and II receptors are present in sma-6, as is the type I specific GS domain (Fig. 1B). SMA-6 contains a 41-amino acid insertion in the kinase domain between residues 491 and 533 which is not found in other type I receptors and which has no detectable motifs. Interestingly, an acidic amino acid modification of the TGFβ type I receptor TβR-I, which renders the kinase constitutively active, 204T→D (Weiser et al., 1995), is an inherent feature of the wild-type form of SMA-6.
Phenotypic analysis of sma-6 alleles
The C. elegans male tail is a sex-specific, bilaterally symmetric copulatory structure comprising of a pair of sharp elongated features known as spicules, which are mechanically required during mating, and rays, which are chemosensory organs which also provide tactile feedback. Each of the nine pairs of rays is unique with respect to morphology and chemosensitivity (Fig. 3A). We were interested in the potential role of sma-6 in tail morphogenesis through participation with sma-2, sma-3, sma-4, and daf-4. Previously, the tail defects in sma-2, sma-3, sma-4, and daf-4 males had been characterized (Estevez et al., 1993; Savage et al., 1996). In each of these mutants, the identity of rays is transformed, leading to a ray fusion defect which can be seen (Fig. 3A,D). The fusion defect has been characterized as a posterior to anterior transformation of identity, which results in a high fusion percentage of rays 4/5, 6/7 and 8/9 (Savage et al., 1996). Furthermore, Sma mutants exhibit a defect in the morphology of the spicules which results in a crumpled appearance of these structures and renders males unable to mate.
We therefore examined the tails of sma-6(e1482) males to look for defects similar to those observed in daf-4 and sma-2, sma-3 and sma-4 mutants, which would indicate that these genes function together in a common signaling pathway. However, sma-6(e1482) males had wild-type tail morphologies. Because the nature of the molecular lesion suggested that the sma-6(e1482) mutation was of insufficient severity to generate tail defects, we sought to further reduce the signaling activity mediated by SMA-6. We used deficiencies in the region, mnDf30 and mnDf96, which correspond to deletions encompassing the sma-6 gene, to generate heterozygous animals that harbored both the e1482 mutation and a deleted copy of sma-6. Tail defects were not observed in males heterozygous for sma-6(e1482) and either deficiency. The finding that sma-6(e1482) did not produce the ray fusions and crumpled spicule defects of the other components in the Sma signaling pathway invited several hypotheses, including the involvement of an unidentified third type I receptor in tail development (Table 1). However, two sources of evidence argued that e1482 was not null and that the generation of null alleles may yield animals with abnormal tail morphologies. First, the observation that sma-6(e1482)/Df animals were considerably smaller than sma-6(e1482) alone argued that sma-6(e1482) was not null. Second, analysis of the molecular lesion in sma-6(e1482), corresponding to a 90A→V change in the primary structure, suggested that this mutation was likely to be relatively weak.
To examine this issue further, we generated additional alleles of sma-6 (see Materials and Methods). Analyses of additional alleles of sma-6 indicated that this gene is required both in determining body size and in male tail morphogenesis, consistent with the view that the canonical sma-6(e1482) allele was hypomorphic. Males homozygous for the sma-6(wk7), sma-6(wk8), or sma-6(wk9) alleles manifest identical tail defects to those in daf-4, and sma-2, sma-3 and sma-4 animals (Fig. 3B and Table 1). The percentage of fusions presented in this work differs from previous analyses of other mutants in the Sma/Mab pathways, such as sma-2, -3, -4 or dbl-1 (Savage et al., 1996; Suzuki et al., 1999) because only complete fusions of individual rays were scored as defects, and when similar criteria are applied, the percentage of fusions is similar (see Materials and Methods). An additional abnormality observed in sma-6 mutant males that has been unreported for daf-4 or sma-2, sma-3 and sma-4 mutants is the occasional absence of ray 5. The cause of this defect in relation to the transformation of ray identity is not currently known.
To determine if these phenotypes represent a null mutation in sma-6, we sequenced the sma-6(wk7) allele and identified the presence of a stop codon in the extracellular region at 72Y. Both the kinase domain and the transmembrane region required for function would be absent in the mutant protein, and therefore it is a molecular null. Furthermore, hemizygous sma-6(wk7)/Df animals did not exhibit a more severe phenotype than sma-6(wk7) homozygotes. In sma-6(wk8) animals, a nucleotide change resulting in the mutant form 445E→D yields a phenotype that closely resembles the null, as judged through several criteria, including comparison with the sma-6(wk7) body size, inspection of the male tail (Table 1), and by analysis of sma-6(wk8)/Df animals. Based on sequence comparison, the mutation in sma-6(wk8) disrupts an extremely conserved residue found in protein kinases. We examined the crystal structures of other serine-threonine and tyrosine kinase domains, and observed that the wk8 mutation would diminish the critical predicted hydrogen-bonding role of the wild-type residue in establishing the framework of the kinase region, primarily with residue 477R.
Differential signaling thresholds for body size and mail tail development
The ability to separate the Sma and Mab phenotypes in both sma-6(e1482) and the previously characterized sma-4(e805) alleles suggest that the body size regulation and male tail development functions may have distinct downstream signaling components. However, alternative hypotheses including different signaling threshold requirements for the two roles are possible. In this model, the separate biological processes each require different levels of signaling activity.
In order to distinguish between these two possibilities, quadruply homozygous sma-6(e1482)unc-4(e120); sma-4(e805); him-5 (e1490) animals were generated and examined for the Mab phenotype. Interestingly, though neither the sma-6(e1482) nor the sma-4(e805) alleles elicit tail defects, animals homozygous for both the sma-6(e1482) and sma-4(e805) mutations exhibit ray fusions at a low penetrance (Table 1). Though crumpled spicules were also seen in this genotype, abnormalities in a single spicule were also observed (data not shown). We conclude that the activity of the sma-6(e1482) loss-of-function allele is sufficient for male tail development, but below the activity required for body size regulation. Furthermore, these data suggest that more signaling is needed for specifying body size than for regulating tail morphogenesis. Consistent with this model, there have been no reported mutations in sma-2, sma-3, sma-4, or sma-6 that only affect tail development but not body size.
sma-6 expression is dynamic
Integrated transgenic lines bearing translational fusions of the sma-6 gene with a lacZ reporter indicate that sma-6 is expressed during embryonic, larval and adult stages (Fig. 4). During the early larval stages (L1-L2), sma-6 is extensively expressed in the anterior pharyngeal and distal posterior regions of the animal (Fig. 4A). Soon afterwards, expression begins in the posterior intestinal nuclei and advances more anteriorly (Fig. 4B). Expression is seen in the pairs of intestinal nuclei as they divide. Strong expression is seen in the pharyngeal muscles of the anterior and posterior bulbs of the pharynx (Fig. 4C). Once the intestinal cell divisions are complete, one can see continued expression in the intestinal cells during L2-L3 (Fig. 4D), and later disappearing in these cells. In adults, the staining pattern disappears from the midsections of the animal and persists in the pharyngeal muscles (Fig. 4E). In males, expression is seen in the tail (Fig. 4F), as predicted, but the identity of the cells is unclear. The pattern of expression in the anterior regions is strikingly similar to those reported for DAF-4/GFP constructs (Patterson et al., 1997), and resembles that of DBL-1, a candidate ligand for SMA-6 (Suzuki et al., 1999). These results are consistent with both the placement of DAF-4 and SMA-6 in a common signaling pathway, and the role of sma-6 in male tail development.
Expression of sma-6 (A-F) using lacZ reporter fusion assays. An integrated transgenic line bearing a translational fusion of lacZ and SMA-6 was used to assess sma-6 transcriptional activity. (A) An L1-L2 animal showing staining in the pharyngeal muscles and posterior regions of the animal. (B) Soon after the expression seen in A, the expression is beginning in the posterior intestinal nuclei and extends anteriorly.(C) Expression continues in the intestinal nuclei as they are dividing and persists in the pharyngeal muscles (arrows point to the pharyngeal muscle nuclei). (D) Staining of intestinal nuclei (arrow points to the lumen of the intestine; L2-L3 animal). (E) Adult staining persists in pharyngeal muscle nuclei; (F) staining in the male tail – the resolution of this lacZ construct does not allow clear identification of the staining cells.
Expression of sma-6 (A-F) using lacZ reporter fusion assays. An integrated transgenic line bearing a translational fusion of lacZ and SMA-6 was used to assess sma-6 transcriptional activity. (A) An L1-L2 animal showing staining in the pharyngeal muscles and posterior regions of the animal. (B) Soon after the expression seen in A, the expression is beginning in the posterior intestinal nuclei and extends anteriorly.(C) Expression continues in the intestinal nuclei as they are dividing and persists in the pharyngeal muscles (arrows point to the pharyngeal muscle nuclei). (D) Staining of intestinal nuclei (arrow points to the lumen of the intestine; L2-L3 animal). (E) Adult staining persists in pharyngeal muscle nuclei; (F) staining in the male tail – the resolution of this lacZ construct does not allow clear identification of the staining cells.
sma-6 expression is also observed in late-stage embryos (data not shown), indicating a possible embryonic requirement that does not affect known phenotypes. Biological activity of sma-6, however, would require the presence of signaling initiators and effectors, particularly the ligand, type II receptor, and downstream Smads. Our observation that the null sma-6(wk7) allele is not lethal implies that complete loss-of-function mutations in other components of the Sma pathway also may not produce lethality. However, we have observed that the fecundity (number of eggs) of hermaphrodites bearing mutations in sma-6 is reduced in several independent outcrossed alleles (data not shown). Mutations in sma-6 may contribute to low levels of embryonic or larval lethality, though a large proportion of animals reach adulthood. Therefore, further investigations are necessary to characterize the developmental role of the embryonic expression, if any.
Signaling specificity and crosstalk
The finding that two parallel signaling pathways which share a type II receptor exists in C. elegans, introduces the potential for mixed signaling, or ‘crosstalk’ between them. Possible interactions between daf-1 and sma-6 were assessed by examining the phenotype of double homozygotes. Mutations in sma-6 were observed to enhance the dauer-constitutive (Daf-c) defects of daf-1 mutants (Table 2). The alleles daf-1(m213) and daf-1(m40) were used to compare the effects of the doubly homozygous state. At temperatures exceeding 15°C, this difference was not observable, as the daf-1 mutations results in a very high frequency of dauered animals (>95%). The enhancement of the Daf-c defect yielded a sensitive in vivo assay to examine crosstalk between the Sma/Mab and dauer pathways. To pursue these indications further, we investigated the genetic interactions between sma-2, sma-4 and daf-1. Because of the large proportion of dauered animals at temperatures greater than or equal to 20° C, these data were only collected at 15° C (Table 2). All combinations of sma-6 and daf-1 alleles that were tested demonstrated enhancement, thereby eliminating the possibility of allele-specific genetic interactions. However, the degree of enhancement varied among the strains, as wk7 exhibited greater enhancement than wk8. sma-4(em269) demonstrated a moderate level of enhancement, whereas sma-2(e297) failed to interact with daf-1. These results provide evidence of possible crosstalk between the Sma and dauer pathways at low levels and may result from ancient evolutionary duplication of the signaling pathways. The fundamental developmental role of each of the two type I receptors, however, is unique because of the failure of null mutations in either daf-1 or sma-6 to generate overlapping mutant phenotypes.
DISCUSSION
The developmental role of sma-6
The results presented indicate that sma-6 is a dpp/BMP-like type I receptor involved in regulating body size and male tail development in C. elegans. Prior to this work, the upstream components of the Sma/Mab pathway were unknown (Savage et al., 1996). Through this investigation, we demonstrate that the phenotypes resulting from mutations in sma-6 are consistent with a model whereby DAF-4, SMA-2, SMA-3, SMA-4 and SMA-6 function in a common developmental pathway (Fig. 5). Recently, mutations in a C. elegans homolog of the dpp /BMP family of ligands have been identified that render it a candidate ligand for SMA-6 based on the similarity of phenotypes with mutations in other components of the Sma/Mab pathway (Suzuki et al., 1999). In parallel, DAF-7, DAF-1, DAF-4, DAF-3, DAF-8, and DAF-14 are involved in the regulation of the dauer pathway through the utilization of the shared type II receptor DAF-4. The genetic analysis of these genes provides in vivo evidence for how specificity is achieved in C. elegans. The ligands of the two pathways primarily interact with only one type I receptor, both of which function with a single common type II receptor, which in turn determines which set of Smads are utilized in downstream signaling events.
A model for TGFβ superfamily signaling in C. elegans. The type II receptor DAF-4 is shared between both developmental pathways, through interaction with the process-specific type I receptor and ligand(s). SMA-6, a type I receptor, transduces the extracellular signal to the downstream effectors SMA-2, SMA-3, and SMA-4 which regulate the expression of downstream targets.The other role of DAF-4 signaling involves the type I receptor DAF-1 and the downstream Smad mediators DAF-3, DAF-8, and DAF-14 (Georgi et al., 1990; Estevez et al., 1993; Ren et al., 1996; Patterson et al., 1997).
A model for TGFβ superfamily signaling in C. elegans. The type II receptor DAF-4 is shared between both developmental pathways, through interaction with the process-specific type I receptor and ligand(s). SMA-6, a type I receptor, transduces the extracellular signal to the downstream effectors SMA-2, SMA-3, and SMA-4 which regulate the expression of downstream targets.The other role of DAF-4 signaling involves the type I receptor DAF-1 and the downstream Smad mediators DAF-3, DAF-8, and DAF-14 (Georgi et al., 1990; Estevez et al., 1993; Ren et al., 1996; Patterson et al., 1997).
The role of TGFβ signaling in determining body size of Sma mutants is unknown. Two general models can be proposed that can account for the body size differences between wild-type animals and animals mutant in the components of the Sma/Mab pathway. First, developmental cues that affect cell migration, division, or lineage specification may be rendered dysfunctional, yielding aberrant numbers or positioning of cells in tissues which are responsive to Sma/Mab pathway signaling. Alternatively, control mechanisms involved in the regulatory phases of the cell cycle may be altered, generating correct lineages and cellular fates, but reduced cell size. The C. elegans cul-1 gene provides an example of the latter mechanism, whereby mutations in a negative cell-cycle regulator result in simultaneous hyperplasia and reduced cell size in affected tissues, leading to developmental arrest and increased body length in mutant animals (Kipreos et al., 1996). The observation that many aspects of TGFβ-like signaling are intimately involved in cell-cycle regulation and differentiation render either of these processes, or a combination of them, possible causes for the primary phenotypes of sma-6 mutants and the Sma pathway in general. We are currently extending our studies to clarify this issue.
The early expression of sma-6 as assayed by reporter fusion suggests a possible embryonic role for the receptor, perhaps one that has not been accounted for by the phenotypes assessed in this study. Alternatively, body size regulation involving the Sma pathway may proceed from early stages of development, or perhaps stages from before which the phenotype is evident. This notion is supported by the observations that animals defective in other components of the Sma pathway exhibit the reduced body size phenotype during late larval stages, and the difference in body size between wild-type and mutant animals continues to increase thereafter. Conversely, animals transformed with a genomic fragment corresponding to the sma-6 gene exhibit increased body length. This result indicates that moderate hyperactivity of the Sma/Mab pathway can exceed the developmental requirement of the signal and suggests that this may be true for other components of the pathway.
There has been much progress in discerning the molecular mechanisms that contribute to male tail morphogenesis and development of the constituent structures. In C. elegans, HOM-C/Hox gene products play a central role in specifying ray identity. The products of mab-5, egl-5, and mab-18 are all required to specify correct ray patterning. Mutations in these genes lead to defects in tail development, including missing and fused rays (Baird et al., 1991; Chisholm, 1991; Chow and Emmons, 1994). Aberrant regulation or dysfunction of these genes and their products in ray precursor or ancestral cells result in transformation of the respective ray identities, thereby contributing to the observed absence and fusion defects. These observations suggest there may be a connection between Hox gene function and the Sma/Mab pathway in ray patterning. In Drosophila, a primary regulatory target of DPP signaling is labial, a Hox gene that is required during midgut morphogenesis (Panganiban et al., 1990). Mutations in the components of the dpp pathway result in diminished expression of labial in response to dpp signal and it has recently been shown that Drosophila MAD binds to labial promoter elements (Szüts et al., 1998). It is possible the C. elegans Smads bind to promoter elements of the recently characterized C. elegans labial homolog ceh-13 (Wittmann et al., 1997), since the expression of a ceh-13∷lacZ reporter is highly diminished in Sma/Mab mutations (Suzuki et al., 1999).
Parallel developmental pathways
The separation of TGFβ signaling in the Sma/Mab and dauer pathways is in marked contrast with RTK pathways. For example, in Drosophila, the receptor tyrosine kinases encoded by sevenless, torso and the EGF receptor DER share a common downstream MAPK signaling cascade, as evident in the ability of a gain-of-function mutation in the downstream MAPK target rolled to activate multiple pathways (Brunner et al., 1994). Also in yeast, Ste11, a component of one of the six known MAP kinase pathways, is used in three signaling pathways that have distinct biological outputs (reviewed by Madhani and Fink, 1998). It is hypothesized that some of the specificity for these three yeast pathways may results from interactions with Ste5, which may assemble the kinases into a complex and prevent crosstalk with other MAP kinase pathways. In contrast, in the C. elegans TGFβ pathways, specificity is achieved by the choice of the type I receptors, SMA-6 and DAF-1, which function with a distinct set of Smads, which in turn bind to specific DNA sequences on promoters. Previous studies of the two vertebrate type I BMP receptors have shown differences in biological outcomes (Zou et al., 1997), but neither these studies, nor biochemical studies, have determined the identity of the intracellular molecules that distinguish these two signals. It is possible that these vertebrate pathways function like their counterparts in C. elegans, but this issue will have to await genetic analysis.
What still remains to be determined in the Sma/Mab pathway is how one signal, one receptor, and one set of Smads, elicits three different developmental events – body size, spicule development and ray development. Presumably, there are additional transcription factors involved, such as a FAST-1 winged helix transcription factor (Chen et al., 1996), that are tissue specific for each of these three developmental events. It will be important to determine if other molecules exist that are required for signaling which bind to the receptors or Smads. Genetic screens are underway that may shed light on this issue. Another unanswered question regarding the Sma/Mab pathway stems from the failure to identify negatively acting Smad members that reduce the primary signaling response, such as Smad6, Smad7 and DAD. It is possible that signaling activity through SMA-6 is only required at discrete intervals during development, and this requirement would obviate the need to competitively regulate the signaling levels. Alternatively, TGFβ signaling may be more rudimentary in C. elegans, with antagonistic Smads being a later development. However, most of the characterized genes and mechanisms involving TGFβ signaling have been highly conserved in C. elegans.
ACKNOWLEGMENTS
The authors would like to thank Y. Suzuki, W. Wood, and N. Ueno for exchanging results prior to publication. We thank C. Savage and S. Cohen for the wk8 and wk11 alleles and useful discussions, G. Patterson, B. Wadsworth and M. Driscoll for useful discussions, D. Portman and S. Emmons for the bx110 allele, D. Riddle for dauer-constitutive strains, the Caenorhabditis Genetics Center for providing nematode strains and the C. elegans Sequencing Consortium for providing sequence. This work was supported by grants from the NIH and the New Jersey Cancer Commission to R. W. P.